PMID- 22825057 OWN - NLM STAT- MEDLINE DCOM- 20130201 LR - 20211203 IS - 1551-4005 (Electronic) IS - 1538-4101 (Print) IS - 1551-4005 (Linking) VI - 11 IP - 15 DP - 2012 Aug 1 TI - TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. PG - 2922-30 LID - 10.4161/cc.21386 [doi] AB - The Hippo signaling pathway regulates cellular proliferation and survival, thus exerting profound effects on normal cell fate and tumorigenesis. We previously showed that the pivotal effector of this pathway, YAP, is amplified in tumors and promotes epithelial-to-mesenchymal transition (EMT) and malignant transformation. Here, we report that overexpression of TAZ, a paralog of YAP, in human mammary epithelial cells promotes EMT and, in particular, some invasive structures in 3D cultures. TAZ also leads to cell migration and anchorage-independent growth in soft agar. Furthermore, we identified amphiregulin (AREG), an epidermal growth factor receptor (EGFR) ligand, as a target of TAZ. We show that AREG functions in a non-cell-autonomous manner to mediate EGF-independent growth and malignant behavior of mammary epithelial cells. In addition, ablation of TEAD binding completely abolishes the TAZ-induced phenotype. Last, analysis of breast cancer patient samples reveals a positive correlation between TAZ and AREG in vivo. In summary, TAZ-dependent secretion of AREG indicates that activation of the EGFR signaling is an important non-cell-autonomous effector of the Hippo pathway, and TAZ as well as its targets may play significant roles in breast tumorigenesis and metastasis. FAU - Yang, Nuo AU - Yang N AD - Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA. FAU - Morrison, Carl D AU - Morrison CD FAU - Liu, Peijun AU - Liu P FAU - Miecznikowski, Jeff AU - Miecznikowski J FAU - Bshara, Wiam AU - Bshara W FAU - Han, Suxia AU - Han S FAU - Zhu, Qing AU - Zhu Q FAU - Omilian, Angela R AU - Omilian AR FAU - Li, Xu AU - Li X FAU - Zhang, Jianmin AU - Zhang J LA - eng GR - P30 CA016056/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20120801 PL - United States TA - Cell Cycle JT - Cell cycle (Georgetown, Tex.) JID - 101137841 RN - 0 (AREG protein, human) RN - 0 (Amphiregulin) RN - 0 (Cell Cycle Proteins) RN - 0 (EGF Family of Proteins) RN - 0 (Glycoproteins) RN - 0 (Intercellular Signaling Peptides and Proteins) RN - 0 (Intracellular Signaling Peptides and Proteins) RN - 0 (Ligands) RN - 0 (Nuclear Proteins) RN - 0 (RNA, Small Interfering) RN - 0 (Trans-Activators) RN - 0 (Transcription Factors) RN - 0 (Transcriptional Coactivator with PDZ-Binding Motif Proteins) RN - 0 (WWTR1 protein, human) RN - 0 (YY1AP1 protein, human) RN - EC 2.7.10.1 (EGFR protein, human) RN - EC 2.7.10.1 (ErbB Receptors) SB - IM MH - Amphiregulin MH - Breast Neoplasms/*metabolism MH - Cell Cycle Proteins MH - Cell Line, Tumor MH - Cell Movement MH - Cell Proliferation MH - *Cell Transformation, Neoplastic MH - EGF Family of Proteins MH - Epithelial Cells/metabolism MH - Epithelial-Mesenchymal Transition MH - ErbB Receptors/*metabolism MH - Female MH - Glycoproteins/genetics/*metabolism MH - Humans MH - Intercellular Signaling Peptides and Proteins/genetics/*metabolism MH - Intracellular Signaling Peptides and Proteins/*metabolism MH - Ligands MH - Mammary Glands, Human/*metabolism/pathology MH - Neoplasm Metastasis MH - Nuclear Proteins/metabolism MH - RNA Interference MH - RNA, Small Interfering MH - Signal Transduction MH - Trans-Activators MH - Transcription Factors MH - Transcriptional Coactivator with PDZ-Binding Motif Proteins PMC - PMC3419062 EDAT- 2012/07/25 06:00 MHDA- 2013/02/05 06:00 PMCR- 2013/08/01 CRDT- 2012/07/25 06:00 PHST- 2012/07/25 06:00 [entrez] PHST- 2012/07/25 06:00 [pubmed] PHST- 2013/02/05 06:00 [medline] PHST- 2013/08/01 00:00 [pmc-release] AID - 21386 [pii] AID - 2012CC4266 [pii] AID - 10.4161/cc.21386 [doi] PST - ppublish SO - Cell Cycle. 2012 Aug 1;11(15):2922-30. doi: 10.4161/cc.21386. Epub 2012 Aug 1.